New insulin biosimilar faces off against market leader in early trial

NCT ID NCT07364669

Completed Disease control Sponsor: Laboratorios Pisa S.A. de C.V. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 1 trial tested whether a new biosimilar insulin called Insulex® R works similarly to the standard Humulin® R. Forty healthy adults received a single injection of each insulin in a crossover design. Researchers measured how the body absorbed the insulin and how it affected blood sugar levels. The goal was to see if the two insulins are comparable, which could offer more options for diabetes treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Insulex® R (biosimilar human insulin)
What this could lead to: If successful, this could show that Insulex® R is a safe and effective alternative to Humulin® R for managing diabetes.
What could go wrong: This is an early Phase 1 study in healthy people, not those with diabetes. It only checks short-term effects, so it may not predict real-world outcomes or long-term safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Locations

Prosciento, Inc

San Diego, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.